

# Recommendations for Parkinson's clinical trials using digital health technologies


Kimberly Ward Barowicz, BS, CAPM, SHRM-CP<sup>1</sup>, Marjan Meinders, PhD<sup>2</sup>, Mark Frasier, PhD<sup>3</sup>, Johan Hellsten, PhD<sup>4#</sup>, Tairmae Kangarloo, BS<sup>5</sup>, Matthew Sullivan, PhD<sup>6#</sup>, Cindy Zadikoff, MD<sup>7</sup>, Martijn Müller<sup>1</sup>, PhD, Diane Stephenson<sup>1</sup>, PhD

<sup>1</sup> Critical Path Institute, Tucson, AZ, USA, <sup>2</sup> Radboud university medical center, Nijmegen, Netherlands, <sup>3</sup> The Michael J. Fox Foundation, New York, NY, USA, <sup>4</sup> H. Lundbeck A/S, Valby, Denmark, <sup>5</sup> Takeda Pharmaceuticals, Lexington, MA, USA<sup>6</sup> Parkinson's UK, London, England, <sup>7</sup> AbbVie Inc., North Chicago, IL, USA, <sup>#</sup>Person with Parkinson's

- Critical Path for Parkinson's consortium's Digital Drug Development Tool (3DT) initiative is a global pre-competitive collaboration to advance digital health technologies (DHT) in Parkinson's.
- 3DT led a task force and produced recommendations and considerations for integrating digital health technologies in Parkinson's clinical studies, prioritizing a participant-centered perspective.
- The work of this collaboration places people with Parkinson's at the center of study design, emphasizing their involvement and needs in the development and implementation of digital health technologies.

Critical Path for  
Parkinson's  
**Digital Drug  
Development  
Tools Initiative  
(3DT)**

**Incorporating the lived of experience is key to expediting the approval of much-needed treatments for individuals with Parkinson's**



## Task Force Outcome

Recommendations in 3 key areas:

Protocol  
Design

Recruitment  
&  
Enrollment

Protocol  
Compliance  
&  
Participant  
Retention



View 3DT's  
recommendations for  
clinical trial design

When using digital health technologies for assessing motor fluctuations or fatigue in Parkinson's, consider tailoring assessments, minimizing burden, and accounting for daily life impact, study duration, frequency of assessments, cultural/socio-economic factors, and the overall lived experience.



View the video poster  
presentation here

For more information about CPP  
please contact Executive Director Dr. Diane Stephenson  
(dstephenson@c-path.org)